Screener
Bicara Therapeutics BCAX Exercised (in shares)
Exercised (in shares) at other companies
Other financials
Where this comes from
Reported directly by Bicara Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice.
The source filing: Bicara Therapeutics’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 4:03 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-033429
| Line item | Shares | Weighted-Average Exercise Price | Weighted Average –Remaining Contractual Life (years) | Aggregate Intrinsic Value (1)(in thousands) |
|---|---|---|---|---|
| Outstanding as of December 31, 2025 | 9,850,977 | $9.03 | ||
| Granted | 2,389,555 | 16.79 | ||
| Exercised | (366,416) | 4.34 | ||
| Canceled | — | — | ||
| Outstanding as of March 31, 2026 | 11,874,116 | 10.74 | 8.56 | $108,757 |
| Exercisable as of March 31, 2026 | 3,349,637 | $7.36 | 7.76 | $42,004 |
| Exercisable and expected to vest as of March 31, 2026 | 11,874,116 | $10.74 | 8.56 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Bicara Therapeutics's exercised (in shares)?
- Bicara Therapeutics (BCAX) reported exercised (in shares) of $4.34 in Q1 2026.
- What does exercised (in shares) mean?
- The weighted average exercise price at which employees and directors exercised their stock options during the period. This provides insight into the historical price levels at which equity incentives were realized by participants.
Ask your AI about Bicara Therapeutics's exercised (in shares).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude